Healthcare Giant Johnson & Johnson Cuts Prostate Cancer Risk by 62 Percent in Landmark Trial

New York, Saturday, 24 October 2026.
Johnson & Johnson demonstrated a 62% reduction in prostate cancer recurrence risk using perioperative Erleada, bolstering its pharmaceutical growth amid corporate portfolio shifts and broader market interest in defensive assets.